Maniakas A, Dadu R, Busaidy NL, et al. - In patients with anaplastic thyroid carcinoma (ATC), researchers assessed rates of overall survival (OS) over the last 2 decades in this single-institution cohort study with 479 patients (246 men [51%]; median age, 65.0 [range, 21.1-92.6] years). They included patients with ATC histopathological confirmation from January 2000 to October 2019 and split them into three categories by whether they presented in 2000-2013, 2014-2016, or 2017-2019. Ranging from 0.01 to 16.63, the median OS of the entire cohort in this study was 0.79 years (9.5 months). It was noted that the OS at 1 and 2 years was 35% and 18% in the 2000-2013 group, 47% and 25% in the 2014-2016 group, and 59% and 42% in the 2017-2019 group, respectively. Targeted therapy, the addition of immunotherapy to targeted therapy, and surgery after neoadjuvant BRAF-directed therapy were factors associated with better OS. A 94% 1-year survival with a median follow-up of 1.21 years was seen in patients undergoing surgery after neoadjuvant BRAF-directed therapy. A significant increase in survival seems related to changes in patient management. With the inclusion of multidisciplinary therapies, like surgery and radiation therapy, once untreatable ATC is now treatable with molecular-based personalized therapies.